Intra-Cellular Therapies Inc.
The company focuses on developing small molecule drugs for neuropsychiatric and neurological disorders. They offer CAPLYTA for schizophrenia and bipolar depression. Lumateperone is in Phase 3 trials for depressive disorders and other indications. The company also develops Lenrispodun for Parkinsons disease and CNS disorders, ITI-1284 for neuropsychiatric disorders in dementia, and ITI-333 for substance use disorders and psychiatric comorbidities.
Overview
Strengths
- No significant strengths identified based on the analyzed metrics.
Weaknesses
- With a depreciation Potential of -97.99%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Analysts expect revenues to decline in the coming year.
- The company has high debt. Net Debt to EBITDA Ratio (2.50) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (14.71%).
- EV/EBITDA (100.00) is significantly higher than the sector mean (51.86).
- The Price to Free Cash Flow ratio (100.00) is significantly higher than the sector mean.
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 2.5 |